ANVS
Annovis Bio
Follow Write Post
ANVS Price Today by TradingView
Add A Trade Add A Catalyst Event
ANVS - Annovis Bio 23:29 PM - Jul 29 2021
by: Maverick

Another reminder to never, ever hold through data.

I exited my main position last night at 110 after I saw the PR hit the wire.

I thought the data looked good (at least reading it the way they presented it).  Only thing that bothered me was how strange (like a kid's science project) the press release looked (arrows didn't line up...and it was just...arrows? no numbers?), which is what pushed me to sell.

I did hold overnight a smaller position in another account that I kept "just in case" the data was as good as it looked.  

I was wrong and took a hit on that position, sold for a loss today at $50 (from $120) 

The shareholders seem to praise the data and ANVS seemed happy about it, but it was trashed by the market and biotech analysts.  One even called it a "zero."

Not sure it's a zero, but they do need to add more patients, which they're doing in the next phase of the trial.

One potential upside:  They do have an FDA decision coming up next month on an application they made for Orphan Drug designation - irpages2.eqs.com/websites/anno...
Read More
0
0
ANVS - Annovis Bio 23:20 PM - Jul 29 2021
by: Maverick

ANVS - Data Release - July 28, 2021


Annovis Bio Presents New Clinical and Biomarker Data at 2021 Alzheimer's Association International Conference - newsfilecorp.com/release/91498...


Read More
0
0
ANVS - Annovis Bio 22:37 PM - Jul 24 2021
by: Maverick

I have updated the upcoming catalysts for ANVS (that I'm aware of).  An important 30-45 days is ahead (including next week)
Read More
0
0
ANVS - Annovis Bio 22:13 PM - Jul 22 2021
by: Maverick

An exciting week coming up for ANVS.  Maria has confirmed that new data will be presented.
Read More
1
0
ANVS - Annovis Bio 22:10 PM - Jul 22 2021
by: Maverick

ANVS - Updates on Phase 2a Trials (AD) at AAIC 2021

irpages2.eqs.com/websites/anno...


Annovis Bio's lead drug candidate, ANVS401, will be featured in a poster presentation: Positive Clinical Outcomes in Two Phase 2a Studies: ADAS-Cog in Alzheimer's and MDS-UPDRS in Parkinson's patients plus Markers of Toxic Cascade that Leads to Nerve Cell Death.

Previously, Annovis Bio reported that AD patients treated with ANVS401 for 25 days showed statistically significant cognitive improvement as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11); PD patients treated with ANVS401 showed statistically significant motor function improvement as measure by the MDS-UPDRS. Additionally, in a test that measures speed and accuracy, AD and PD patients both responded with a statistically significant increase in correctly coded fields. The company also measured inflammatory factors and found statistically significant lowering of these factors. These tests were part of the Company's ongoing Phase 2a study in AD and PD patients.

Read More
1
0
ANVS - Annovis Bio 00:18 AM - Jul 19 2021
by: Maverick

Wow, what a ride this one has been.  Final exits were $100 to $120 (from as low as 47)
Read More
1
0
ANVS - Annovis Bio 00:59 AM - Jun 23 2021
by: Maverick

I am not sure what happened here today, but I didn't like it. 😬

I am not aware of anything that's changed - so sticking with the plan.
Read More
0
0
ANVS - Annovis Bio 01:27 AM - Jun 13 2021
by: Maverick

ANVS - Annovis Bio - DD - June 2021

  • Current Price (June 13): 91.00 (found at 47)
  • O/S 7M
  • Float 4.7M
  • Cash ~50M
  • Market cap: ~$700M

annovisbio.com

Pipeline: annovisbio.com/technologies

Our Pipeline consists of drugs for chronic neurodegeneration - Alzheimer’s disease (AD), its orphan indication Alzheimer’s disease and dementia in Down syndrome (AD-DS) and Parkinson’s disease (PD). Additionally, we have a compound to treat acute neurodegeneration - traumatic brain injury (TBI) and stroke - and a third compound for advanced AD.

We Are Working to REVERSE the Toxic Cascade

Recent updates

June 2021 Investor Presentation (must read) - irpages2.eqs.com/download/comp...

Upcoming catalysts
  • Phase 2 full data July / August 2021 for ANVS401  -- Alzheimer’s disease (AD) and Parkinson’s disease (PD) - they haven't said a date yet, but I'm guessing it'll be at the AAIC on July 26-30 -- alz.org/aaic/overview.asp (they are a platinum sponsor...)

Heads up
As always, there's two major warnings with any biotech: data could turn out bad (despite expectations otherwise) and offerings are ever looming (since most biotechs have no revenue).  I wouldn't be surprised to see an offering in late June/early July if this price stays up here.

My notes
  • They recently did an offering of 1M shares @ 50, putting $50M in the coffers
  • As you can see from the trades on this board, I ran into this around 47.  It. moves. fast.  I currently have no position (have bought and sold several times), but I'll be back in by end of June ahead of data release in July
  • I really like this one.  I can't find any reason to dislike it, even at 90.
Read More
1
8
ANVS - Annovis Bio 22:55 PM - Jun 21 2021
by: Maverick

Has spiked over a 100 a few times the last few days.  HOLDING.
Read More
0
0

Annovis Bio - ANVS

Total Followers: 1
ANVS Chart by TradingView
Follow
Latest ANVS News
Link Copied to Clipboard!